Ironshore Pharmaceuticals & Development, Inc.

ironshore pharmaceuticals & development, inc., is leveraging its proprietary technology, delexis®, to optimize the delivery of previously approved drug products. the company’s lead product candidates, hld-200 and hld-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat adhd and are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. intended for nighttime dosing, delexis® is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of adhd symptoms immediately upon wakening and throughout the day. ironshore pharmaceuticals & development, inc. is a wholly owned subsidiary of highland therapeutics, inc.